Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Intangibles (2018 - 2024)

Akebia Therapeutics (AKBA) has disclosed Intangibles for 7 consecutive years, with $9.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Intangibles fell 80.0% to $9.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was $9.0 million, a 80.0% decrease, with the full-year FY2023 number at $36.0 million, down 50.0% from a year prior.
  • Intangibles was $9.0 million for Q3 2024 at Akebia Therapeutics, down from $18.0 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $282.1 million in Q1 2020 to a low of $9.0 million in Q3 2024.
  • A 5-year average of $87.9 million and a median of $72.1 million in 2022 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: decreased 11.43% in 2020, then tumbled 80.0% in 2024.
  • Akebia Therapeutics' Intangibles stood at $144.2 million in 2020, then dropped by 25.0% to $108.1 million in 2021, then tumbled by 33.33% to $72.1 million in 2022, then plummeted by 50.0% to $36.0 million in 2023, then crashed by 75.0% to $9.0 million in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Intangibles are $9.0 million (Q3 2024), $18.0 million (Q2 2024), and $27.0 million (Q1 2024).